CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice.
We have evaluated alum, immunostimulatory cytosine guanine dinucleotide-containing oligodeoxy-nucleotides (CPG ODN), and an alum/CPG ODN combination as adjuvants with hepatitis B surface antigen, to compare their potential to allow lower doses of antigen to be used for induction of humoral responses. BALB/c mice were immunized by intramuscular injection with 0.01, 0.1 or 1.0 micro g recombinant hepatitis B surface antigen without adjuvant or with alum and/or CPG ODN added. When given without adjuvant or with alum, each 10-fold decrease in amount of antigen resulted in a similarly reduced titre of antibody against hepatitis B surface antigen. In contrast, CPG ODN, on its own or combined with alum, allowed high anti-hepatitis B surface antigen titres even with a 1000-fold reduction in amount of antigen. These findings may have important immunological and economical consequences for vaccine development.
Weeratna
Risini
R
Coley Pharmaceutical Group, Kanata and Ottawa Hospital Research Institute (Loeb Campus), Ottawa, Ontario, Canada. rweeratna@coleypharma.com
Comanita
Lacrimioara
L
Davis
Heather L
HL
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000534:Alum Compounds / Q000494:pharmacology; D000818:Animals; D018899:CpG Islands / Q000502:physiology; D005260:Female; D006509:Hepatitis B / Q000276:immunology* / Q000517:prevention & control; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009841:Oligonucleotides / Q000378:metabolism*; D014612:Vaccines / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D006514:Hepatitis B Surface Antigens; D009841:Oligonucleotides; D014612:Vaccines; C041524:aluminum sulfate